Diabetic retinopathy

January 17, 2019

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Fasudil, Epicatechin and Matrine (FEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 17/January/2018, 11.41 pm

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]
January 4, 2019

RNA-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  lncRNA TUG1, Epicatechin and Matrine (TUG1EM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 5/January/2018, 12.04 am

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]
December 21, 2018

Molecular therapy for TIIDM and Metabolic defects:Mesencephalic astrocyte-derived neurotrophic factor (MANF)  increases Sirtuin-4 expression, augments insulin secretion, reduces metabolic stress, improves glucose uptake, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 21/December/2018, 10.43 pm

Introduction: What they say A study from the “Duke Molecular Physiology Institute and Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC […]
December 21, 2018

Activator protein(AP-1)-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  a chemical compound that induces  AP-1 activity, Epicatechin and Matrine (VAEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/December/2018, 10.32 pm

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for […]